{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:20Z","timestamp":1789239980295,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>There is a lack of high-quality data informing the optimal antithrombotic drug strategy following bioprosthetic heart valve replacement or valve repair. Disparity in recommendations from international guidelines reflects this. This study aimed to document current patterns of antithrombotic prescribing after heart valve surgery in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>All UK consultant cardiac surgeons were e-mailed a custom-designed survey. The use of oral anticoagulant (OAC) and\/or antiplatelet drugs following bioprosthetic aortic valve replacement or mitral valve replacement, or mitral valve repair (MVrep), for patients in sinus rhythm, without additional indications for antithrombotic medication, was assessed. Additionally, we evaluated anticoagulant choice following MVrep in patients with atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>We identified 260 UK consultant cardiac surgeons from 36 units, of whom 103 (40%) responded, with 33 units (92%) having at least 1 respondent. The greatest consensus was for patients undergoing bioprosthetic aortic valve replacement, in which 76% of surgeons favour initial antiplatelet therapy and 53% prescribe lifelong treatment. Only 8% recommend initial OAC. After bioprosthetic mitral valve replacement, 48% of surgeons use an initial OAC strategy (versus 42% antiplatelet), with 66% subsequently prescribing lifelong antiplatelet therapy. After MVrep, recommendations were lifelong antiplatelet agent alone (34%) or following 3\u2009months OAC (20%), no antithrombotic agent (20%), or 3\u2009months OAC (16%). After MVrep for patients with established atrial fibrillation, surgeons recommend warfarin (38%), a direct oral anticoagulant (37%) or have no preference between the 2 (25%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>There is considerable variation in the use of antithrombotic drugs after heart valve surgery in the UK and a lack of high-quality evidence to guide practice, underscoring the need for randomized studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/icvts\/ivae089","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:07:28Z","timestamp":1714637248000},"source":"Crossref","is-referenced-by-count":2,"title":["Antithrombotic therapy after heart valve surgery: contemporary practice in the UK"],"prefix":"10.1093","volume":"38","author":[{"given":"Nabila","family":"Laskar","sequence":"first","affiliation":[{"name":"Department of Cardiology, Barts Heart Centre , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D","family":"Bayliss","sequence":"additional","affiliation":[{"name":"Newcastle University and the Academic Cardiovascular Unit, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust , Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal H","family":"Kirmani","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Liverpool Heart & Chest Hospital , Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guys & St Thomas\u2019 Hospitals , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Maier","sequence":"additional","affiliation":[{"name":"Newcastle University and the Academic Cardiovascular Unit, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust , Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman P","family":"Briffa","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Northern General Hospital , Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Northern General Hospital , Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-6483","authenticated-orcid":false,"given":"Simon","family":"Kendall","sequence":"additional","affiliation":[{"name":"Newcastle University and the Academic Cardiovascular Unit, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust , Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-7311","authenticated-orcid":false,"given":"Benoy Nalin","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wessex Cardiac Centre, Southampton General Hospital , Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-3579","authenticated-orcid":false,"given":"Enoch","family":"Akowuah","sequence":"additional","affiliation":[{"name":"Newcastle University and the Academic Cardiovascular Unit, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust , Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"key":"2024052205054690400_ivae089-B1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jtcvs.2011.04.048","article-title":"Aortic valve surgery: marked increase in the volume and significant decrease in mechanical valve use\u2014an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National Database","volume":"142","author":"Dunning","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024052205054690400_ivae089-B2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0003-4975(10)62496-4","article-title":"Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement","volume":"34","author":"Ionescu","year":"1982","journal-title":"Ann Thorac Surg"},{"key":"2024052205054690400_ivae089-B3","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"key":"2024052205054690400_ivae089-B4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2016.11.021","article-title":"Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial","volume":"150","author":"Rafiq","year":"2017","journal-title":"Thromb Res"},{"key":"2024052205054690400_ivae089-B5","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2012.54506","article-title":"Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding","volume":"308","author":"M\u00e9rie","year":"2011","journal-title":"JAMA"},{"key":"2024052205054690400_ivae089-B6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/CIRCOUTCOMES.115.002696","article-title":"Safety and use of anticoagulation after aortic valve replacement with bioprostheses: a meta-analysis","volume":"9","author":"Riaz","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2024052205054690400_ivae089-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10557-020-07069-8","article-title":"Comparison of antithrombotic strategies in Chinese patients in sinus rhythm after bioprosthetic mitral valve replacement: early outcomes from a multicenter registry in China","volume":"35","author":"Zhang","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024052205054690400_ivae089-B8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11239-018-1724-0","article-title":"Antithrombotic therapy after mitral valve repair: VKA or aspirin?","volume":"46","author":"Van der Wall","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2024052205054690400_ivae089-B9","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2024052205054690400_ivae089-B10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"43","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"2024052205054690400_ivae089-B11","doi-asserted-by":"crossref","first-page":"e038001","DOI":"10.1136\/bmjopen-2020-038001","article-title":"Identifying research priorities in cardiac surgery: a report from the James Lind Alliance Priority Setting Partnership in adult heart surgery","volume":"10","author":"Lai","year":"2020","journal-title":"BMJ Open"},{"key":"2024052205054690400_ivae089-B12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jtcvs.2014.01.004","article-title":"Reduced anticoagulation after mechanical aortic valve replacement: interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial","volume":"147","author":"Puskas","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024052205054690400_ivae089-B13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"2024052205054690400_ivae089-B14","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.amjcard.2017.02.015","article-title":"Management of major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants compared with warfarin in clinical practice (from phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II])","volume":"119","author":"Steinberg","year":"2017","journal-title":"Am J Cardiol"},{"key":"2024052205054690400_ivae089-B15","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet."},{"key":"2024052205054690400_ivae089-B16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2024052205054690400_ivae089-B17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2024052205054690400_ivae089-B18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"2024052205054690400_ivae089-B19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"2024052205054690400_ivae089-B20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: a randomized, multicentre, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve","volume":"227","author":"Jawitz","year":"2022","journal-title":"Am Heart J"},{"key":"2024052205054690400_ivae089-B21","author":"Artivion","year":"2022"},{"key":"2024052205054690400_ivae089-B22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jacc.2007.10.058","article-title":"Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications","volume":"51","author":"Russo","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2024052205054690400_ivae089-B23","author":"National Institute for Health and Care Excellence [NICE]","year":"2021"}],"container-title":["Interdisciplinary CardioVascular and Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/icvts\/advance-article-pdf\/doi\/10.1093\/icvts\/ivae089\/57405528\/ivae089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/38\/5\/ivae089\/57805180\/ivae089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/38\/5\/ivae089\/57805180\/ivae089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T01:55:25Z","timestamp":1716342925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/icvts\/article\/doi\/10.1093\/icvts\/ivae089\/7665160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/icvts\/ivae089","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.05.22283122","asserted-by":"object"}]},"ISSN":["2753-670X"],"issn-type":[{"value":"2753-670X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,5,1]]},"article-number":"ivae089"}}